Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Top Cited Papers
- 1 October 2005
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 366 (9493), 1279-1289
- https://doi.org/10.1016/s0140-6736(05)67528-9
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent From Glycemic ControlJournal of the American College of Cardiology, 2005
- Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimensDiabetologia, 2005
- ThiazolidinedionesNew England Journal of Medicine, 2004
- A desktop guide to Type 2 diabetes mellitusDiabetic Medicine, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionNew England Journal of Medicine, 1998
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994
- Group sequential procedures: Calendar versus information timeStatistics in Medicine, 1989
- Banting lecture 1988. Role of insulin resistance in human diseaseDiabetes, 1988